---
title: "INSILICO has been included in the Hang Seng Composite Index and is expected to become a target for the Hong Kong Stock Connect"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275891647.md"
description: "On February 13, the Hang Seng Index Company announced the quarterly review results of the Hang Seng Index series as of December 31, 2025, in which INSILICO was included in the Hang Seng Composite Index. The changes will take effect after the market closes on March 6, 2026 (Friday) and will be effective from March 9, 2026 (Monday), at which point the Shanghai and Shenzhen Stock Exchanges will adjust the scope of investable stocks under the Hong Kong Stock Connect accordingly. According to a research report by CICC, INSILICO may be included in the Hong Kong Stock Connect as it meets a series of criteria including market capitalization, liquidity, and listing time. On February 10, INSILICO announced that the group has reached a strategic cooperation in drug research and development with CMS. Through this cooperation, both parties will achieve a series of AI-powered innovative drug research and development collaborations on multiple projects in the fields of central nervous system and autoimmune diseases. According to the terms of the cooperation agreement, both parties will combine INSILICO's validated AI platform and AI-enabled innovative drug R&D capabilities with CMS's experienced R&D team and deep understanding of disease areas to jointly promote the collaborative development of no less than 2 R&D projects. At the same time, INSILICO is expected to receive research and development funding support of up to tens of millions of Hong Kong dollars for each project"
datetime: "2026-02-13T11:25:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275891647.md)
  - [en](https://longbridge.com/en/news/275891647.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275891647.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275891647.md) | [繁體中文](https://longbridge.com/zh-HK/news/275891647.md)


# INSILICO has been included in the Hang Seng Composite Index and is expected to become a target for the Hong Kong Stock Connect

According to Zhitong Finance APP, on February 13, the Hang Seng Index Company announced the quarterly review results of the Hang Seng Index series as of December 31, 2025, in which INSILICO (03696) was included in the Hang Seng Composite Index. The changes will be implemented after the market closes on March 6, 2026 (Friday) and will take effect from March 9, 2026 (Monday), at which time the Shanghai and Shenzhen Stock Exchanges will adjust the scope of investable stocks under the Hong Kong Stock Connect accordingly. According to a research report by CICC, INSILICO may be included in the Hong Kong Stock Connect as it meets a series of criteria including market capitalization, liquidity, and listing time.

On February 10, INSILICO announced that the group has reached a strategic cooperation agreement with CMS for drug research and development. Through this cooperation, both parties will achieve a series of AI-enabled innovative drug research and development collaborations on multiple projects in the fields of central nervous system and autoimmune diseases.

According to the terms of the cooperation agreement, both parties will combine INSILICO's validated AI platform and AI-enabled innovative drug research and development capabilities with CMS's experienced research and development team and deep understanding of disease areas to jointly promote the cooperative development of no less than two research and development projects. At the same time, INSILICO is expected to receive research and development funding support of up to tens of millions of Hong Kong dollars for each project

### Related Stocks

- [CSOP HS TECH (03033.HK)](https://longbridge.com/en/quote/03033.HK.md)
- [INSILICO (03696.HK)](https://longbridge.com/en/quote/03696.HK.md)
- [CMS (00867.HK)](https://longbridge.com/en/quote/00867.HK.md)

## Related News & Research

- [InSilico Medicine Boosts AI Platform and Advances Clinical Pipeline](https://longbridge.com/en/news/280916373.md)
- [InSilico Expands AI-Driven CNS Collaboration With Tenacia in USD94.75 Million Deal](https://longbridge.com/en/news/280541264.md)
- [MedPal AI Wins Strong Shareholder Backing at AGM as It Expands AI Health Platform](https://longbridge.com/en/news/281501359.md)
- [Insig AI Plans Growth Drive and Eyes Nasdaq Dual Listing](https://longbridge.com/en/news/281311983.md)
- [InSilico Out-licensed Drug ISM4808 Begins Clinical Trial](https://longbridge.com/en/news/278010381.md)